A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: wheel (17), pedals (5)

RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB-VINCRISTINE (RCVP) Regimen Lymphoma – RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine Indication Non-Hodgkin’s Lymphoma Toxicity
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf

RCHOP(14)-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine (14) Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE- (14) (RCHOP 14) There are multiple versions of this protocol in use. Please
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCHOP14-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine-14-Ver-1.2.pdf

RCEOP-Cyclophosphamide-Etoposide-Prednisolone-Rituximab-Vincristine Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-ETOPOSIDE-PREDNISOLONE-RITUXIMAB-VINCRISTINE Regimen (RCEOP) Lymphoma – RCEOP-Cyclophosphamide-Etoposide-Prednisolone-RituximabVincristine Indication Non Hodgkin’s Lymphoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCEOP-Cyclophosphamide-Etoposide-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf

Pembrolizumab_400mg (lymphoma)

Description
Chemotherapy Protocol LYMPHOMA Pembrolizumab (400mg) Regimen • Lymphoma – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg (lymphoma)

Description
Chemotherapy Protocol LYMPHOMA Pembrolizumab (200mg) Regimen • Lymphoma – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-200mg.pdf

Nivolumab (lymphoma)

Description
Chemotherapy Protocol LYMPHOMA Nivolumab Regimen • Lymphoma – Nivolumab Indication • Nivolumab is recommended as an option for treating relapsed or refractory classical Hodgkin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab.pdf

Nivolumab 240mg (lymphoma)

Description
Chemotherapy Protocol LYMPHOMA Nivolumab (240mg-14 days) Regimen • Lymphoma – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended as an option for
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab-240mg.pdf

GemP-Cisplatin-Gemcitabine-Methylprednisolone Ver 1.3

Description
Chemotherapy Protocol LYMPHOMA CISPLATIN-GEMCITABINE-METHYLPREDNISOLONE (GemP) Regimen Lymphoma – GemP-Cisplatin-Gemcitabine-Methylprednisolone Indication Non-Hodgkin’s Lymphoma Hodgkin’s Lymphoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/GemP-Cisplatin-Gemcitabine-Methylprednisolone-Ver-1.3.pdf

MyelomaVTDBortezomib(SC)DexamethasoneThalidomideVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA VTD (SC-28)-BORTEZOMIB (SC)-DEXAMETHASONE-THALIDOMIDE (28 day) Regimen Multiple Myeloma – VTD (28)-Bortezomib (SC)-Dexamethasone
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVTDBortezomibSCDexamethasoneThalidomideVer1.pdf

MyelomaVTDBortezomib(IV)DexamethasoneThalidomideVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA VTD (IV-28)-BORTEZOMIB (IV)-DEXAMETHASONE-THALIDOMIDE (28 day) Regimen Multiple Myeloma – VTD (IV-28)-Bortezomib (IV
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVTDBortezomibIVDexamethasoneThalidomideVer1.pdf
391 to 400 of 1000
Previous … 38 39 40 41 42 … Next